Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU -- Studies include both biologic naïve...
Clinical Trial
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
Complete enrollment achieved nearly six months ahead of plan Top-line data now anticipated mid-2025 Addition of second-line cholangiocarcinoma arm to...
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to CalidiSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE)...
Aruna Bio Announces Issuance of U.S. Patent for Composition of Matter for Neural Exosomes Used to Deliver Therapeutics to the Brain
On track to initiate Phase 1b/2a clinical trial of AB126 in acute ischemic stroke in 2H 2024BOSTON and ATHENS, Ga.,...
Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
Funding to accelerate development of RECCE® 327 Gel (R327G) for acute treatment of burn wound infections and downstream bacterial complications...
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing...
Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
Late Breaking Clinical Trial Presentations to Feature Additional Results from SEQUOIA-HCM Related to Patient-Reported Health Status, Cardiac Structure and Function and...
Seyltx Announces Positive Pre-Clinical Dose-Ranging Data with Its Selective Oral Small-Molecule Inhibitor of GluN2B Illustrating Near-Complete Suppression of Refractory Chronic Cough within the Therapeutic Index
- Results will be presented at the London International Cough Symposium on July 18, 2024 - Dose dependent cough suppression...
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden...
SamanTree Medical Raises $14M in Series B Financing Round to Support Global Expansion and Innovation in Surgical Treatment
Henry Charlton and Claire Poulard to join the Board of Directors Funding will Accelerate US Market Entry, Enhance Digital Solutions,...
Pharmaceutical Quality Management Systems Market to Be Worth $4.59 Billion by 2031 – Exclusive Report by Meticulous Research®
REDDING, Calif., July 15, 2024 /PRNewswire/ -- According to a new market research report titled, 'Pharmaceutical Quality Management Systems Market Size,...
Signant Health Appoints 20-Year Life Sciences Veteran Paul Richmond to Executive Leadership Team as Chief Commercial Officer
PHILADELPHIA, July 15, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment...
JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS
LAS VEGAS, July 12, 2024 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a multidisciplinary organization with a focus on fintech and...
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner
DENVER, July 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports the initial commercial sale...
Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
LOUISVILLE, Ky., July 12, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a...
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST...